Biotechnology company Inspire Pharmaceuticals said its drug candidate for dry eye disease did not meet its key treatment goals in a Phase III clinical trial. Inspire said it is reviewing its six-week trial of Prolacria (diquafosol tetrasodium ophthalmic solution) in 490 patients.
Biotechnology company Inspire Pharmaceuticals said its drug candidate for dry eye disease did not meet its key treatment goals in a Phase III clinical trial.
Inspire said it is reviewing its six-week trial of Prolacria (diquafosol tetrasodium ophthalmic solution) in 490 patients.
Shares of Inspire dropped in premarket trading to $5.29 from their close of $6.61 on 20 January, according to The Associated Press.
